Click here to get full coverage on IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer - CancerNetwork

IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer  CancerNetwork

IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer - CancerNetwork

Click here to get full coverage on Bull Run: What analysts say about IMNN stock - July 2025 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn

Bull Run: What analysts say about IMNN stock - July 2025 PostEarnings & Capital Efficient Trading Techniques  baoquankhu1.vn

Bull Run: What analysts say about IMNN stock - July 2025 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn

Click here to get full coverage on Ovarian cancer drug adds 13 months survival in early trial data - Stock Titan

Ovarian cancer drug adds 13 months survival in early trial data  Stock Titan

Ovarian cancer drug adds 13 months survival in early trial data - Stock Titan

Click here to get full coverage on ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Clinical Trials Arena

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer  Clinical Trials Arena

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Clinical Trials Arena

Click here to get full coverage on Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer - OncLive

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer  OncLive

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer - OncLive

Click here to get full coverage on FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer - Targeted Oncology

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer  Targeted Oncology

FDA Backs Phase 3 Study of IMNN-001 in Advanced Ovarian Cancer - Targeted Oncology

Click here to get full coverage on IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial… - Zacks Small Cap Research

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…  Zacks Small Cap Research

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial… - Zacks Small Cap Research

Click here to get full coverage on IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress - GlobeNewswire

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress  GlobeNewswire

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress - GlobeNewswire

Click here to get full coverage on Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More  Yahoo Finance

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance

Click here to get full coverage on IMUNON Advances IMNN-001 in Pivotal Phase 3 Trial for Advanced Ovarian Cancer, New Data Presented at AACR Conference - Quiver Quantitative

IMUNON Advances IMNN-001 in Pivotal Phase 3 Trial for Advanced Ovarian Cancer, New Data Presented at AACR Conference  Quiver Quantitative

IMUNON Advances IMNN-001 in Pivotal Phase 3 Trial for Advanced Ovarian Cancer, New Data Presented at AACR Conference - Quiver Quantitative

Click here to get full coverage on Aug Breakouts: Is IMNN stock a defensive play in 2025 - GDP Growth & Weekly Return Optimization Plans - Bộ Nội Vụ

Aug Breakouts: Is IMNN stock a defensive play in 2025 - GDP Growth & Weekly Return Optimization Plans  Bộ Nội Vụ

Aug Breakouts: Is IMNN stock a defensive play in 2025 - GDP Growth & Weekly Return Optimization Plans - Bộ Nội Vụ

Click here to get full coverage on IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup - CancerNetwork

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup  CancerNetwork

IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup - CancerNetwork

Click here to get full coverage on IMUNON (NASDAQ: IMNN) posts webcast replay, slides on OVATION 3 and Phase 2 MRD - Stock Titan

IMUNON (NASDAQ: IMNN) posts webcast replay, slides on OVATION 3 and Phase 2 MRD  Stock Titan

IMUNON (NASDAQ: IMNN) posts webcast replay, slides on OVATION 3 and Phase 2 MRD - Stock Titan

Click here to get full coverage on Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges  Yahoo Finance

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Click here to get full coverage on Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer - Clinical Trials Arena

Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer  Clinical Trials Arena

Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer - Clinical Trials Arena

Click here to get full coverage on Institution Moves: How buybacks impact IMNN stock value - CPI Data & Community Verified Watchlist Alerts - Bộ Nội Vụ

Institution Moves: How buybacks impact IMNN stock value - CPI Data & Community Verified Watchlist Alerts  Bộ Nội Vụ

Institution Moves: How buybacks impact IMNN stock value - CPI Data & Community Verified Watchlist Alerts - Bộ Nội Vụ

Click here to get full coverage on IMUNON, Inc. Advances Enrollment in Phase 3 OVATION 3 Study, Paving the Way for Future BLA Filing and Potential Breakthrough in Ovarian Cancer Treatment - Quiver Quantitative

IMUNON, Inc. Advances Enrollment in Phase 3 OVATION 3 Study, Paving the Way for Future BLA Filing and Potential Breakthrough in Ovarian Cancer Treatment  Quiver Quantitative

IMUNON, Inc. Advances Enrollment in Phase 3 OVATION 3 Study, Paving the Way for Future BLA Filing and Potential Breakthrough in Ovarian Cancer Treatment - Quiver Quantitative

Click here to get full coverage on IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer  Yahoo Finance

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - Yahoo Finance

Click here to get full coverage on IMUNON, Inc. to Host Investor Event in New York City on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Ovarian Cancer - Quiver Quantitative

IMUNON, Inc. to Host Investor Event in New York City on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Ovarian Cancer  Quiver Quantitative

IMUNON, Inc. to Host Investor Event in New York City on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Ovarian Cancer - Quiver Quantitative

Click here to get full coverage on Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Cure Today

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer  Cure Today

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer - Cure Today

Click here to get full coverage on IMUNON, Inc. to Host Investor Event on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Advanced Ovarian Cancer - Quiver Quantitative

IMUNON, Inc. to Host Investor Event on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Advanced Ovarian Cancer  Quiver Quantitative

IMUNON, Inc. to Host Investor Event on November 10, 2025, Featuring Updates on Phase 3 Study of IMNN-001 for Advanced Ovarian Cancer - Quiver Quantitative

Click here to get full coverage on Imunon looks for an IL-12 Ovation | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Imunon looks for an IL-12 Ovation | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Imunon looks for an IL-12 Ovation | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Click here to get full coverage on IMNN Looks Ahead to Promising 2026 with Key Developments - GuruFocus

IMNN Looks Ahead to Promising 2026 with Key Developments  GuruFocus

IMNN Looks Ahead to Promising 2026 with Key Developments - GuruFocus

Click here to get full coverage on Imunon, Inc. Announces CFO Transition - TradingView — Track All Markets

Imunon, Inc. Announces CFO Transition  TradingView — Track All Markets

Imunon, Inc. Announces CFO Transition - TradingView — Track All Markets

Click here to get full coverage on IMUNON Announces Stock Dividend Boosting Shareholder Value - Yahoo Finance

IMUNON Announces Stock Dividend Boosting Shareholder Value  Yahoo Finance

IMUNON Announces Stock Dividend Boosting Shareholder Value - Yahoo Finance

Click here to get full coverage on IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - Chartmill

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules  Chartmill

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - Chartmill

Click here to get full coverage on IMNN: First Site Activated for Phase 3 OVATION 3 Trial… - Yahoo Finance

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…  Yahoo Finance

IMNN: First Site Activated for Phase 3 OVATION 3 Trial… - Yahoo Finance

Click here to get full coverage on IMUNON’s Stacy Lindborg on the long road to Phase III - The Pharma Letter

IMUNON’s Stacy Lindborg on the long road to Phase III  The Pharma Letter

IMUNON’s Stacy Lindborg on the long road to Phase III - The Pharma Letter

Click here to get full coverage on The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer - Cure Today

The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer  Cure Today

The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer - Cure Today

Click here to get full coverage on Imunon announces up to $9.75M private placement priced at-the-market - Yahoo Finance

Imunon announces up to $9.75M private placement priced at-the-market  Yahoo Finance

Imunon announces up to $9.75M private placement priced at-the-market - Yahoo Finance

Click here to get full coverage on Companies To Watch: Imunon - Life Science Leader

Companies To Watch: Imunon  Life Science Leader

Companies To Watch: Imunon - Life Science Leader

Click here to get full coverage on Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing - TradingView — Track All Markets

Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing  TradingView — Track All Markets

Imunon Inc - Interim CFO Kimberly Graper To Resign January 14, 2026 - SEC Filing - TradingView — Track All Markets

Click here to get full coverage on Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Yahoo Finance

Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer  Yahoo Finance

Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer - Yahoo Finance

Click here to get full coverage on Imunon receives Nasdaq exception to address listing deficiencies and amends stock plan - Investing.com

Imunon receives Nasdaq exception to address listing deficiencies and amends stock plan  Investing.com

Imunon receives Nasdaq exception to address listing deficiencies and amends stock plan - Investing.com

Click here to get full coverage on IMUNON Announces Webcast of In-Person R&D Day Highlighting - GlobeNewswire

IMUNON Announces Webcast of In-Person R&D Day Highlighting  GlobeNewswire

IMUNON Announces Webcast of In-Person R&D Day Highlighting - GlobeNewswire

Click here to get full coverage on IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules  GlobeNewswire

IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewswire

Click here to get full coverage on IMUNON, Inc. Hosts Update on Ovarian Cancer Treatment Advancements at R&D Day Event in New York City - Quiver Quantitative

IMUNON, Inc. Hosts Update on Ovarian Cancer Treatment Advancements at R&D Day Event in New York City  Quiver Quantitative

IMUNON, Inc. Hosts Update on Ovarian Cancer Treatment Advancements at R&D Day Event in New York City - Quiver Quantitative

Click here to get full coverage on IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagion Live

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants  Contagion Live

IMUNON’s IMNN-101 Vaccine Shows Promising Results in Phase 1 Trial, Demonstrates Cross-Reactivity Against COVID Variants - Contagion Live

Click here to get full coverage on Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com

Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues  Investing.com

Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com

Click here to get full coverage on IMNN Stock Price, News & Analysis - Stock Titan

IMNN Stock Price, News & Analysis  Stock Titan

IMNN Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Imunon shares soar on promising ovarian cancer trial results - Investing.com

Imunon shares soar on promising ovarian cancer trial results  Investing.com

Imunon shares soar on promising ovarian cancer trial results - Investing.com

Click here to get full coverage on Earnings call transcript: Imunon Q3 2025 sees stock volatility post-call - Investing.com

Earnings call transcript: Imunon Q3 2025 sees stock volatility post-call  Investing.com

Earnings call transcript: Imunon Q3 2025 sees stock volatility post-call - Investing.com

Click here to get full coverage on IMUNON announces reverse stock split - MSN

IMUNON announces reverse stock split  MSN

IMUNON announces reverse stock split - MSN

Click here to get full coverage on Imunon Announces CFO Transition and Reappointment of Jeffrey Church - TipRanks

Imunon Announces CFO Transition and Reappointment of Jeffrey Church  TipRanks

Imunon Announces CFO Transition and Reappointment of Jeffrey Church - TipRanks

Click here to get full coverage on IMUNON announces 1-for-15 reverse stock split to maintain Nasdaq listing - Investing.com

IMUNON announces 1-for-15 reverse stock split to maintain Nasdaq listing  Investing.com

IMUNON announces 1-for-15 reverse stock split to maintain Nasdaq listing - Investing.com

Click here to get full coverage on Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Ad - GuruFocus

Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Ad  GuruFocus

Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Ad - GuruFocus

Click here to get full coverage on Imunon Announces $7 Million Registered Direct Offering - TipRanks

Imunon Announces $7 Million Registered Direct Offering  TipRanks

Imunon Announces $7 Million Registered Direct Offering - TipRanks

Click here to get full coverage on Imunon Stock Surges as Positive Study Findings Propel Advanced Cancer Treatment - StocksToTrade

Imunon Stock Surges as Positive Study Findings Propel Advanced Cancer Treatment  StocksToTrade

Imunon Stock Surges as Positive Study Findings Propel Advanced Cancer Treatment - StocksToTrade

Click here to get full coverage on Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued  Stocktwits

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued - Stocktwits

Click here to get full coverage on IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference  GlobeNewswire

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire

Click here to get full coverage on IMUNON provides updates on ovarian cancer immunotherapy program - Investing.com

IMUNON provides updates on ovarian cancer immunotherapy program  Investing.com

IMUNON provides updates on ovarian cancer immunotherapy program - Investing.com

Click here to get full coverage on Brookline Capital lowers Imunon stock price target to $16 on offering dilution - Investing.com UK

Brookline Capital lowers Imunon stock price target to $16 on offering dilution  Investing.com UK

Brookline Capital lowers Imunon stock price target to $16 on offering dilution - Investing.com UK

Click here to get full coverage on Imunon Stock Surge: Real Deal or Fleeting High? - StocksToTrade

Imunon Stock Surge: Real Deal or Fleeting High?  StocksToTrade

Imunon Stock Surge: Real Deal or Fleeting High? - StocksToTrade

Click here to get full coverage on Imunon Inc.: Is It A Good Buy Now? - StocksToTrade

Imunon Inc.: Is It A Good Buy Now?  StocksToTrade

Imunon Inc.: Is It A Good Buy Now? - StocksToTrade

Click here to get full coverage on Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon - Stocktwits

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon  Stocktwits

Imunon Jumps 96% On Phase 2 Immune Biomarker Data Reveal Ahead of ESMO Congress; Retail Expects ‘Major’ Partnership News Soon - Stocktwits

Click here to get full coverage on Imunon Granted Nasdaq Exception to Regain Compliance - TipRanks

Imunon Granted Nasdaq Exception to Regain Compliance  TipRanks

Imunon Granted Nasdaq Exception to Regain Compliance - TipRanks

Click here to get full coverage on Imunon Announces Private Placement Agreement with Investors - TipRanks

Imunon Announces Private Placement Agreement with Investors  TipRanks

Imunon Announces Private Placement Agreement with Investors - TipRanks

Click here to get full coverage on IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer - OncLive

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer  OncLive

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer - OncLive

Click here to get full coverage on New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

New Phase II data confirm promise of Imunon’s IMMN-001  The Pharma Letter

New Phase II data confirm promise of Imunon’s IMMN-001 - The Pharma Letter

Click here to get full coverage on Imunon Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks

Imunon Announces Reverse Stock Split to Meet Nasdaq Rules  TipRanks

Imunon Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks

Click here to get full coverage on IMNN-001/Chemo Improves Survival in Advanced Ovarian Cancer - CancerNetwork

IMNN-001/Chemo Improves Survival in Advanced Ovarian Cancer  CancerNetwork

IMNN-001/Chemo Improves Survival in Advanced Ovarian Cancer - CancerNetwork

Click here to get full coverage on IMUNON continues subject enrolment in Phase I/II ovarian cancer trial - Clinical Trials Arena

IMUNON continues subject enrolment in Phase I/II ovarian cancer trial  Clinical Trials Arena

IMUNON continues subject enrolment in Phase I/II ovarian cancer trial - Clinical Trials Arena

Click here to get full coverage on Imunon faces Nasdaq delisting over share price rule - Investing.com

Imunon faces Nasdaq delisting over share price rule  Investing.com

Imunon faces Nasdaq delisting over share price rule - Investing.com

Click here to get full coverage on IMNN - Imunon Inc Latest Stock News & Market Updates - Stock Titan

IMNN - Imunon Inc Latest Stock News & Market Updates  Stock Titan

IMNN - Imunon Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on What makes IMNN stock attractive today - 2025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts - bollywoodhelpline.com

What makes IMNN stock attractive today - 2025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts  bollywoodhelpline.com

What makes IMNN stock attractive today - 2025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts - bollywoodhelpline.com

Click here to get full coverage on Head to Head Review: Allogene Therapeutics (NASDAQ:ALLO) and Imunon (NASDAQ:IMNN) - Defense World

Head to Head Review: Allogene Therapeutics (NASDAQ:ALLO) and Imunon (NASDAQ:IMNN)  Defense World

IMNN

Price Chart

Key Statistics

Technicals

About IMNN

Latest News

IMNN-001/Chemo Displays TME Shift in Newly Diagnosed Ovarian Cancer - CancerNetwork

Bull Run: What analysts say about IMNN stock - July 2025 PostEarnings & Capital Efficient Trading Techniques - baoquankhu1.vn

Ovarian cancer drug adds 13 months survival in early trial data - Stock Titan

Advanced Charts

Top Gainers

Top Losers